NEXTECH ONCOLOGY SCSP
Venture capitalSenningerberg · 8 people tracked
Find your way into NEXTECH ONCOLOGY SCSP
Fund manager profile
NEXTECH ONCOLOGY SCSP is a venture fund manager based in Senningerberg. SEC filings show 2 venture funds on record, most recently Nextech VII Oncology SCSp filed April 2023.
Source: SEC EDGAR Form D filings. Firm website data not yet available.
Team · 8 people
from public directoriesWhat they invest in
from 3 of 3 portfolio companiesBiotech ×3Medical Devices ×2AI & Machine Learning ×1Deep Tech ×1Healthtech ×1
HQs:United States×2
Investments · 3 tracked
founders shown can be your intro path
Boundless Bio develops precision oncology medicines targeting ecDNA-amplified cancers, specifically creating a new category of ecDNA-directed therapies for patients with oncogenic alterations.
BiotechMedical DevicesLa Jolla, US
Zachary D. Hornby(Executive Officer, Director)inRobert Doebele(Chief Medical Officer)inChristian Hassig(Chief Scientific Officer)Jessica Oien(Chief Legal Officer and Corporate Secretary)in
BoardBenjamin Cravatt, Ph.D.(Director)Kristina Burow(Director)in
Co-investorsARCH Venture PartnersNextech InvestRA Capital
Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.
AI & Machine LearningBiotechDeep TechMedical Devices
Mathai Mammen(CEO, President and Chairman)in
Co-investorsARCH Venture PartnersCatalio Capital Management, LPForesite CapitalFrazier Life SciencesGeneral CatalystNextech Invest+7 more
.png)
Tyra is developing oral dabogratinib, a small-molecule therapy being evaluated in clinical studies for skeletal dysplasia and urologic cancers.
BiotechHealthtechCarlsbad, US
Todd Harris, Ph.D.(Executive Officer, Director)Hiroomi Tada, M.D., Ph.D.(Executive Officer)Daniel Bensen(Executive Officer)inAlan Fuhrman(Executive Officer)inTodd Harris(President, Chief Executive Officer and Director)inBhavesh Ashar(Chief Operating Officer)in
Co-investorsAlta PartnersBioBritNextech InvestCanaan PartnersRA Capital
Exits · 3
IPOs and acquisitions across the tracked portfolioBoundless BioNASDAQ: BOLDParabilis MedicinesNASDAQ: PBLSTYRA BiosciencesNASDAQ: TYRA
Portfolio news
latest coverage across their companiesTYRA Biosciences · stocktitan.net · Aug 14, 2026
Parabilis Medicines · pharmexec.com · Jun 19, 2026
IPO stake values · per SEC filings · 3
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Parabilis Medicines | 3.5% | $20.00 | Jun 2026 | $83.3M |
| TYRA Biosciences | 4.6% | $16.00 | Sep 2021 | $30.3M |
| Boundless Bio | 5.3% | $16.00 | Mar 2024 | $18.8M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- Where is NEXTECH ONCOLOGY SCSP located?
- NEXTECH ONCOLOGY SCSP is headquartered in Senningerberg.